引用本文:吉庆伟.白介素-37b与动脉粥样硬化的基础与临床研究进展[J].中国临床新医学,2019,12(5):474-477.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 126次   下载 87 本文二维码信息
码上扫一扫!
分享到: 微信 更多
白介素-37b与动脉粥样硬化的基础与临床研究进展
吉庆伟
100029 北京,首都医科大学附属北京安贞医院急诊危重症中心
摘要:
[摘要] 白介素(IL)-37b是最近才被命名的白介素-1家族新成员,具有强大的抗炎作用。研究发现,动脉粥样硬化性疾病患者循环和斑块内IL-37b表达显著升高,与预后密切相关。动物实验表明,无论是内源性还是外源性IL-37b都具有显著的抗动脉粥样硬化作用。IL-37b可能成为动脉粥样硬化性疾病防治的新靶点。
关键词:  白介素-37b  炎症  动脉粥样硬化
DOI:10.3969/j.issn.1674-3806.2019.05.02
分类号:R 543.5
基金项目:国家自然科学基金资助项目(编号:81560085)
IL-37b and atherosclerosis: from bench to bedside
JI Qing-wei
Emergency & Critical Care Center, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing 100029, China
Abstract:
[Abstract] Interleukin-37b(IL-37b) is a novel anti-inflammatory cytokine in the interleukin-1 ligand family. Accumulating evidence has demonstrated that both circulating and local IL-37b levels are increased in the patients with atherosclerotic disease and associated with an adverse outcome, and some experimental studies have showed that both exogenous IL-37b and endogenous IL-37b protect mice from atherosclerosis, which indicates that IL-37b may be a novel therapeutic target in prevention and treatment of atherosclerotic disease.
Key words:  Interleukin-37b(IL-37b)  Inflammation  Atherosclerosis